High prevalence of HIV-1 transmitted drug resistance and factors associated with time to virological failure and viral suppression in Taiwan.

BACKGROUND Integrase strand transfer inhibitor (InSTI)-based regimens have become the major first-line treatment for HIV-1-infected patients in Taiwan. Transmitted drug resistance (TDR) and several clinical characteristics are associated with time to virological failure or viral suppression; however, these have not been investigated in Taiwan. OBJECTIVES To determine the impact of several factors on treatment outcomes in HIV-1-infected patients in Taiwan. METHODS The cohort included 164 HIV-1 treatment-naive patients in Taiwan from 2018 to 2020. Blood specimens were collected to determine the genotypic drug resistance using the Stanford University HIV drug resistance database. Cox proportional hazards models were used to identify factors associated with time to virological failure or viral suppression. RESULTS The prevalence of TDR in Taiwan was 27.4% and an increasing trend was seen from 2018 to 2020. TDR mutations related to NNRTIs were the most prevalent (21%) while TDR to InSTIs remained at a relatively low level (1.3%). A baseline HIV-1 viral load of ≥100 000 copies/mL was associated with a shorter time to virological failure [multivariate hazard ratio (mHR) 7.84; P = 0.018] and longer time to viral suppression (mHR 0.46; P < 0.001). Time to viral suppression was shorter in patients receiving InSTI-based regimens (mHR 2.18; P = 0.006). Different InSTI-based regimens as initial treatment did not affect the treatment outcomes. CONCLUSIONS This study found an increasing trend of HIV-1 TDR prevalence from 2018 to 2020 in Taiwan. Baseline HIV-1 viral load and receiving InSTI-based regimens are important factors associated with time to virological failure or viral suppression.

[1]  Jianhua Hou,et al.  Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis , 2021, Frontiers in Pharmacology.

[2]  P. Kaleebu,et al.  HIV drug resistance among adults initiating antiretroviral therapy in Uganda , 2021, The Journal of antimicrobial chemotherapy.

[3]  M. Gordon,et al.  HIV-1 integrase strand transfer inhibitors: A review of current drugs, recent advances and drug resistance. , 2021, International journal of antimicrobial agents.

[4]  Chia-Lung Tsai,et al.  Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19. , 2020, The Journal of antimicrobial chemotherapy.

[5]  A. Trkola,et al.  Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Volberding,et al.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. , 2020, JAMA.

[7]  B. Gazzard,et al.  Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV , 2019, Journal of virus eradication.

[8]  Philip L. Tzou,et al.  Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. , 2019, The Journal of antimicrobial chemotherapy.

[9]  W. Chan,et al.  Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County , 2019, Heliyon.

[10]  Y. Chen,et al.  Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan , 2019, BMC Infectious Diseases.

[11]  Hongzhou Lu,et al.  Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China , 2019, BMC Infectious Diseases.

[12]  O. Ogbuagu,et al.  Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting , 2018, Medicine.

[13]  D. Shortino,et al.  Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States , 2018, AIDS research and human retroviruses.

[14]  Y. Chen,et al.  HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan , 2018, Oncotarget.

[15]  R. Xin,et al.  Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing , 2018, Epidemiology and Infection.

[16]  C. Katlama,et al.  Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen , 2017, The Journal of antimicrobial chemotherapy.

[17]  R. Wanyenze,et al.  Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.

[18]  C. Fraser,et al.  Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom , 2016, HIV medicine.

[19]  J. Miro,et al.  Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection , 2017, The Journal of antimicrobial chemotherapy.

[20]  K. White,et al.  Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naïve Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens. , 2017, The Journal of infectious diseases.

[21]  Hsin-Yun Sun,et al.  Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan , 2016, Scientific Reports.

[22]  S. Little,et al.  Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis , 2016, Scientific Reports.

[23]  H. Günthard,et al.  Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. , 2016, The Journal of infectious diseases.

[24]  Y. Chen,et al.  Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in Southern Taiwan. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[25]  J. Gallant,et al.  Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.

[26]  H. Masur,et al.  Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care – Washington, DC* , 2016, AIDS care.

[27]  J. Baeten,et al.  Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. , 2016, AIDS research and human retroviruses.

[28]  O. Levina,et al.  Psychiatric Distress, Drug Use, and HIV Viral Load Suppression in Russia , 2016, AIDS and Behavior.

[29]  Wen‐Chun Liu,et al.  Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. , 2016, The Journal of antimicrobial chemotherapy.

[30]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[31]  P. Tien,et al.  Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. , 2015, AIDS patient care and STDs.

[32]  N. Abrescia,et al.  Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients. , 2015, AIDS reviews.

[33]  A. Kelleher,et al.  Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis , 2014, AIDS.

[34]  D. Katzenstein,et al.  Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[35]  D. Kuritzkes,et al.  Patients Infected with CRF07_BC Have Significantly Lower Viral Loads than Patients with HIV-1 Subtype B: Mechanism and Impact on Disease Progression , 2014, PloS one.

[36]  J. Eron,et al.  Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Soo-Yon Rhee,et al.  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. , 2014, The Journal of antimicrobial chemotherapy.

[38]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[39]  C. Stephan,et al.  Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials * , 2013, HIV medicine.

[40]  Sally S Bebawy,et al.  Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  M. Cavassini,et al.  Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study , 2012, Journal of acquired immune deficiency syndromes.

[42]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.

[43]  Hsin-Yun Sun,et al.  Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. , 2012, The Journal of antimicrobial chemotherapy.

[44]  H. Günthard,et al.  Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[46]  T. F. Rinke de Wit,et al.  HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia , 2010, Journal of acquired immune deficiency syndromes.

[47]  Susan P. Holmes,et al.  Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations , 2010, The Journal of antimicrobial chemotherapy.

[48]  M. Poljak,et al.  Transmission of drug-resistant HIV-1 is stabilizing in Europe. , 2009, The Journal of infectious diseases.

[49]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[50]  M. de Béthune,et al.  Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors , 2009, Antiviral therapy.

[51]  Tommy F. Liu,et al.  Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations , 2008, Journal of Virology.

[52]  A. Mocroft,et al.  Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study , 2008, Journal of acquired immune deficiency syndromes.

[53]  B. Young,et al.  The prevalence of transmitted antiretroviral drug resistance in treatment‐naïve patients and factors influencing first‐line treatment regimen selection , 2008, HIV medicine.

[54]  Jörg Schüpbach,et al.  Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey , 2007, AIDS.

[55]  P. Harrigan,et al.  Why are Baseline HIV RNA Levels 100,000 Copies/mL or Greater Associated With Mortality After the Initiation of Antiretroviral Therapy? , 2005, Journal of acquired immune deficiency syndromes.

[56]  M. Kozal,et al.  Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  P. Harrigan,et al.  Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. , 2003, The Journal of infectious diseases.

[58]  Bradley J. Betts,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database. , 2003, Nucleic acids research.

[59]  A. d’Arminio Monforte,et al.  Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. , 2002, Archives of internal medicine.

[60]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[61]  G. Skowron,et al.  Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. , 2001 .

[62]  G. Skowron,et al.  Baseline CD4+ Cell Count, Not Viral Load, Correlates With Virologic Suppression Induced by Potent Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[63]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.